In re: Application of Ekwuribe et al.

Serial No.: 09/430,735 Filed: 29 October 1999

Page 11

At page 48, line 4, please replace the term "-200C" with the term -- -20°C --.

At page 48, lines 6 and 10, please replace the term "25°C" with the term -- 25°C --.

At page 48, line 11, please insert the term -- (SEQ ID NO:1) -- after the term cetylenkephalin.

At page 48, lines 11, 17, 19 and 21, please insert the term -- (SEQ ID NO:1) -- after the term "cetyl-TEG-enkephalin".

At page 48, line 11, please replace the term ", μ M" with the term -- μ M --.

In the Claims:

Please amend the claims as follows

Pls Note: Claim 52 was cancel per and+C.

 \geq

47. (Twice Amended) The method of Claim 46 wherein the opioid is

[met⁵]enkephalin (SEQ ID NO:48).

52. (Amended) An amphiphilic oligomer-enkephalin conjugate selected from the group consisting of:

|| H₂N-Tyr-Gly-Gly-Phe-Met-Lys-C-OH

HN—C(O)-OC₂H₄-OC₂H₄-N-C(O)CH₂CH₂-(CH=CH=CH₂)₆CH₃ (SEQ ID NO:1)

H₂N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

 $HN - C(O) - OC_2H_4 - OC_2H_4 - N - C(O)(CH_2)_7 - CH = CH - CH_2 - CH = CH - CH_2 - CH_3$ (SEQ ID NO:1);

In re: Application of Ekwuribe et al.

Serial No.: 09/430,735 Filed: 29 October 1999

Page 12

H2N-Tyr-Gly-Gly-Phe-Met-Lys-COOH

$$HN - C(O) - OC_2H_4 - OC_2H_4 - O-(CH_2)_{15} - CH_3$$
 (SEQ ID NO:1)

 $H_2N\text{-}Tyr\text{-}Gly\text{-}Gly\text{-}Phe\text{-}Met\text{-}Lys\text{-}COOH$

$$\dot{HN}$$
— C(O)-O-(C₂H₄O)₃-C(O)-(CH₂)₁₄-CH₃ (SEQ ID NO:1); and

C(O)-O-(C₂H₄O)₃-C(O)-(CH₂)₁₄-CH₃

| HN-Tyr-Gly-Gly-Phe-Met-Lys-COOH

| HN-C(O)-O-(C₂H₄O)₃-C(O)-(CH₂)₁₄-CH₃ (SEQ ID NO:2).

- Hz
- 83. (Amended) A method for inducing analysesia comprising administering to a subject in need thereof an analysesia-inducing amount of a cetyl-PEG₂-enkephalin (SEQ ID NO:1) conjugate.
- 66
- 84. (Amended) A method for inducing analysesia comprising administering to a subject in need thereof an analysesia-inducing amount of a DHA-PEG₂-enkephalin <u>SEQ ID</u> <u>NO:1)</u> conjugate.
- 92. (Amended) The method of claim 46 wherein the drug-oligomer conjugate has a formula:

Serial No.: 09/430,735 Filed: 29 October 1999

Page 13

93. (Amended) The method of claim 46 wherein the drug-oligomer conjugate has a formula:

94. (Amended) The method of claim 46 wherein the drug-oligomer conjugate has a formula:

$$\begin{array}{c} O \\ || \\ H_2\text{N-Tyr-Gly-Gly-Phe-Met-Lys-C-OH} \\ N - C - OC_2H_4OC_2H_4 - O - (CH_2)_{15} - CH_3 \\ H \quad || \\ O \end{array} \quad \underbrace{(\textbf{SEQ ID NO:1})}_{\textbf{CO:1}}.$$

95. (Amended) The method of claim 46 wherein the drug-oligomer conjugate has a formula:

$$\begin{array}{c} O \\ || \\ H_2 N\text{-Tyr-Gly-Gly-Phe-Met-Lys-C-OH} \\ N - C\text{-O-CH}_2(C_2 H_4 O)_2\text{-CH}_2\text{-C-O} \\ H \quad || \\ O \end{array} \qquad \underbrace{(\textbf{S EQ ID NO:1})}_{\textbf{S EQ ID NO:1}}.$$

96. (Amended) The method of claim 46 wherein the drug-oligomer conjugate has a formula: